Background Unfractionated heparin (UFH) is mostly obtained from porcine and bovine mucosa and has been widely used for the treatment and prevention of thrombotic events. It consists of molecular chains of various lengths varying from 2000 to 40,000 Da [1]. Low molecular weight heparins (LMWHs) are smaller chains of UFH that can be obtained, from unfractionated heparin, by various chemical and e...

Abstract—The objective of this study is to analyze the prophylactic usage of low molecular weight heparin (LMWH) along pregnancy and the correlation between their usage and month/week of pregnancy, in the Department of Gynecology and Obstetrics, at Clinical Hospital in Tetovo. A retrospective study was undertaken during 01 January – 31 December 2012. Over of one year, the total number of patien...

TO THE EDITOR: The well-performed and important FRAGMATIC (Dalteparin in Preventing Blood Clots in Patients With Lung Cancer) trial reported by Macbeth et al concluded that the addition of prophylactic doses of the lowmolecular weight heparin (LMWH) dalteparin for 24 weeks to standard of care in patients with lung cancer did not improve overall survival; the rate of venous thromboembolism was s...

“blood” volume requires overtransfusion with whole blood, plasma, and other iso-oncotic products. Although “congestion” on this basis alone was once spoken of, it is a now a rare event. Until the pulmonary edema associated with the transfusion of packed RBCs and plasma derivatives (TRALI) is reported together with accurate infused volumes of crystalloid and colloid, and concurrent changes in pa...

Thrombin has many biological properties similar to those of growth factors. In a previous study, we showed that thrombin improves healing of the rat tendo Achillis. Low molecular weight heparin (LMWH) inhibits the activity and the generation of thrombin. We therefore considered that LMWH at a thromboprophylactic dose might inhibit tendon repair. Transection of the tendo Achillis was carried out...

cofactor required for ristocetin. Fractionation of heparin yielded preparations that varied in molecular weight and, within a given molecular weight fraction, in affinity for antithrombin III. Fractions of high molecular weight (average 20,000) were more reactive with platelets than were fractions of low molecular weight (7,000). Anticoagulant activity did not parallel the platelet reactivity o...

BACKGROUND The safety and efficacy of taking low-molecular-weight heparin at home was previously demonstrated in a clinical trial in which patients with acute proximal deep vein thrombosis were randomized to receive either intravenous standard heparin in the hospital or subcutaneous low-molecular-weight heparin administered primarily at home. Treatment in the home has the potential to substanti...

BACKGROUND An intravenous course of unfractionated heparin adjusted on the basis of the activated partial thromboplastin time is the initial treatment of choice for most patients with venous thromboembolism. Recently introduced low-molecular-weight heparin preparations can be administered subcutaneously, once or twice daily, without laboratory monitoring. We quantitatively assessed the relative...